The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Bibliographic Details
Main Authors: Anna Vidal-Crespo, Vanina Rodriguez, Alba Matas-Cespedes, Eriong Lee, Alfredo Rivas-Delgado, Eva Giné, Alba Navarro, Sílvia Beà, Elias Campo, Armando López-Guillermo, Monica Lopez-Guerra, Gaël Roué, Dolors Colomer, Patricia Pérez-Galán
Format: Article
Language:English
Published: Ferrata Storti Foundation 2017-11-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/8265

Internet

https://haematologica.org/article/view/8265

Similar Items